|Last Price$15.59||Day Change (%)0.65%|
|Open Price$15.45||Day Change ($)0.10|
|Day Range15.33–15.59||52-Week Range13.13–16.25|
As of Fri 05/24/2013 01:28 PM EDT | USD
Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer
Oncolytics Biotech® Inc. Announces First Quarter 2013 Results
Active Biotech and Ipsen Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer
Capstone Mining to Purchase Pinto Valley Copper Mine
Ipsen’s First Quarter 2013 Sales
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
A curious move, at a curious time, for purportedly, a curious reason, that is also a slap in the face to CPAs with the PFS credential.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...